We investigated the effect of PLK1 inhibition on pancreatic cancer cells using NMS-P937, a selective PLK1 inhibitor (PLK1i), which has 5000-fold higher selectivity than PLK2/PLK352 (Supplementary Fig. 3a). This evidence concerns the gene PLK2 and familial pancreatic carcinoma.